Award
National Institute of Allergy and Infectious Diseases 1R21AI199908-01
Combining CRISPR-Cas9 base editing and proteomics to determine how filovirus VP24 proteins modulate ubiquitination and viral replication
Recipient
National Institute of Allergy and Infectious Diseases (NIAID), part of NIH
Award Amount
$462,000.00
Ceiling
$462,000.00
Awarded
June 16, 2026
Identifier
1R21AI199908-01
NIH awarded a research project to study how filovirus VP24 proteins affect ubiquitination and viral replication using CRISPR-Cas9 base editing and proteomics, funded for 2026-2028.
Description
The project involves studying filoviruses, including Marburg virus (MARV) and Měnglà virus (MLAV), focusing on VP24 proteins and their role in ubiquitination pathways. The award supports research at the NIH, specifically under PA-25-304. The project is funded for fiscal year 2026-2028. The project aims to define ubiquitin-regulated pathways affected by VP24 proteins and their impact on viral replication.